Infinimmune
Infinimmune is an Alameda, California biotechnology company discovering antibody therapeutics from sequenced human immune repertoires.
Founded
2022Infinimmune is an Alameda, California biotechnology company discovering antibody therapeutics from sequenced human immune repertoires.
Infinimmune's Complete Human sequencing and Anthrobody library-on-B-cell platform identify fully paired antibody sequences from human donors. Its official site says the process can screen up to 300 million B cells across more than 350 targets, using native specificity, cross-reactivity and affinity to select candidates.
The GLIMPSE antibody language model supports computational characterization and diversification, followed by wet-lab validation. The same technologies support internal immunology programs and partnered discovery work with Merck.
Source: infinimmune.com
Infinimmune advances human-derived antibody programs for immunology indications. Its current pipeline lists IFX-101 for atopic dermatitis, IFX-201 for IL-13 inhibition, and earlier programs aimed at IgA nephropathy and ulcerative colitis.
The company is developing internal drug candidates while also using its discovery platform in external collaborations. Its 2026 Merck agreement covers multiple antibody targets with an upfront payment and contingent milestones; the official site also identifies a partnership with Immunome.
Source: infinimmune.com
Infinimmune's buyer-facing offering is an antibody discovery and engineering platform built on Complete Human sequencing, the Anthrobody library-on-B-cell technology, and the GLIMPSE antibody language model. The platform sequences fully paired, antigen-specific antibodies from large B-cell populations across hundreds of targets.
Internal pipeline programs derived from the platform include IFX-101, IFX-201, IFX-301, IFX-401, and IFX-501, alongside partnered discovery work such as the research collaboration with Immunome.
Source: infinimmune.com